Precision Medicine

Vélez, Gabriel; Roybal, C. Nathaniel; Colgan, Diana F.; Tsang, Stephen H.; Bassuk, Alexander G.; Mahajan, Vinit B.

doi:10.1001/jamaophthalmol.2015.5934

Cited by 54 publications

(38 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, at the time of the diagnosis, there was no sign indicating the autoimmune retinopathy. Guided by cytokine profiling, presence of antibodies against S‐arrestin (known cause of autoimmune uveitis) was assessed and confirmed the molecular‐based diagnosis . Hence, earlier and more effective therapeutic intervention could be possible.…”

Section: From Proteomics To Personalized Medicinementioning

confidence: 89%

“…Improvements have been made concerning the use of molecular profiling to guide the therapeutic intervention across a broad range of pathological conditions in the field of oncology, cardiology and ophthalmology, and chronic kidney disease (CKD) . Patient stratification was performed on the basis of proteome analysis alone, or in combination with multi ‐omics profiling data from tissue or body fluids.…”

Section: From Proteomics To Personalized Medicinementioning

confidence: 99%

“…In a study by Kartashova et al., treatment selection for patients with isolated systolic hypertension was performed on the basis of plasma proteome‐based interactome network, while Velez et al. applied cytokine profiling of vitreous fluid biopsy to support the therapy of patients with posterior uveitis . Cytokine profiling data from 20 subjects (15 patients with different types of uveitis and five controls) were used to better characterize a new disease case initially diagnosed with idiopathic uveitis.…”

Section: From Proteomics To Personalized Medicinementioning

confidence: 99%

See 2 more Smart Citations

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Latosinska

Frantzi

Vlahou

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of -omics-based approaches. Proteomics attract high interest, as proteins reflect a "real-time" dynamic molecular phenotype. Focusing on proteomics applications for personalized medicine, a literature search was conducted to cover: a) disease prevention, b) monitoring/ prediction of treatment response, c) stratification to guide intervention, and d) identification of drug targets. The review indicates the potential of proteomics for personalized medicine by also highlighting multiple challenges to be addressed prior to actual implementation. In oncology, particularly bladder cancer, application of precision medicine appears especially promising. The high heterogeneity and recurrence rates together with the limited treatment options, suggest that earlier and more efficient intervention, continuous monitoring, and the development of alternative therapies could be accomplished by applying proteomics-guided personalized approaches. This notion is backed by studies presenting biomarkers that are of value in patient stratification and prognosis, and by recent studies demonstrating the identification of promising therapeutic targets. Herein, we aim to present an approach whereby combining the knowledge on biomarkers and therapeutic targets in bladder cancer could serve as basis towards proteomics-guided personalized patient management.

show abstract

Section: From Proteomics To Personalized Medicinementioning

confidence: 89%

Section: From Proteomics To Personalized Medicinementioning

confidence: 99%

Section: From Proteomics To Personalized Medicinementioning

confidence: 99%

See 1 more Smart Citation

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Latosinska

Frantzi

Vlahou

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…12 Proteomic analysis of the adjacent vitreous may serve as way to indirectly biopsy the diseased retina and identify changes in its proteome. 15 – 19 …”

Section: Liquid Biopsy Techniques For Ophthalmic Tissuesmentioning

confidence: 99%

Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease

Vélez

Tang

Cabral

et al. 2018

Trans. Vis. Sci. Tech.

Self Cite

View full text Add to dashboard Cite

Proteomic analysis is an attractive and powerful tool for characterizing the molecular profiles of diseased tissues, such as the vitreous. The complexity of data available for analysis ranges from single (e.g., enzyme-linked immunosorbent assay [ELISA]) to thousands (e.g., mass spectrometry) of proteins, and unlike genomic analysis, which is limited to denoting risk, proteomic methods take snapshots of a diseased vitreous to evaluate ongoing molecular processes in real time. The proteome of diseased ocular tissues was recently characterized, uncovering numerous biomarkers for vitreoretinal diseases and identifying protein targets for approved drugs, allowing for drug repositioning. These biomarkers merit more attention regarding their therapeutic potential and prospective validation, as well as their value as reproducible, sensitive, and specific diagnostic markersTranslational RelevancePersonalized proteomics offers many advantages over alternative precision-health platforms for the diagnosis and treatment of vitreoretinal diseases, including identification of molecular constituents in the diseased tissue that can be targeted by available drugs.

show abstract

“…Alterations in the inflammatory cells, autoantibodies, cytokines, chemokines and soluble adhesion molecules have been reported, most recently erythrocyte sedimentation rate (ESR), plasma cells, interleukin-29/interferon-λ1, S100A8/A9, and S100A12 (108–118). The analysis of tear fluid for biomarkers in chronic anterior non-infectious uveitis is a potential non-invasive collection method (119–121). With further developments in research and science, the potential exists to utilize markers to inform clinicians of optimal therapy choice as we gain more insight into promising drug targets.…”

Section: Treatmentmentioning

confidence: 99%

An Update on Treatment of Pediatric Chronic Non-infectious Uveitis

Sood

Angeles‐Han

2017

Curr Treat Options in Rheum

View full text Add to dashboard Cite

Opinion Statement There are no standardized treatment protocols for pediatric non-infectious uveitis. Topical corticosteroids are the typical first-line agent, although systemic corticosteroids are used in intermediate, posterior and panuveitic uveitis. Corticosteroids are not considered to be long-term therapy due to potential ocular and systemic side effects. In children with severe and/or refractory uveitis, timely management with higher dose disease-modifying antirheumatic drugs (DMARDs) and biologic agents is important. Increased doses earlier in the disease course may lead to improved disease control and better visual outcomes. In general, methotrexate is the usual first-line steroid-sparing agent and given as a subcutaneous weekly injection at >0.5 mg/kg/dose or 10–15 mg/m2 due to better bioavailability. Other DMARDs, for instance mycophenolate, azathioprine, and cyclosporine are less common treatments for pediatric uveitis. Anti-tumor necrosis factor-alpha agents, primarily infliximab and adalimumab are used as second line agents in children refractory to methotrexate, or as first-line treatment in those with severe complicated disease at presentation. Infliximab may be given at a minimum of 7.5 mg/kg/dose every 4 weeks after loading doses, up to 20 mg/kg/dose. Adalimumab may be given up to 20 or 40 mg weekly. In children who fail anti-tumor necrosis factor-alpha agents, develop anti-tumor necrosis factor-alpha antibodies, experience adverse effects, or have difficulty with tolerance, there is less data available regarding subsequent treatment. Promising results have been noted with tocilizumab infusions every 2–4 weeks, abatacept monthly infusions and rituximab.

show abstract

Precision Medicine

Cited by 54 publications

References 14 publications

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease

An Update on Treatment of Pediatric Chronic Non-infectious Uveitis

Contact Info

Product

Resources

About